Dr. David Braun highlights that the LITESPARK-022 trial demonstrated improved disease-free survival with pembrolizumab plus belzutifan in high-risk RCC, helping address recurrence despite standard adjuvant therapy. He also discusses LITESPARK-011, where lenvatinib plus belzutifan showed superior efficacy over cabozantinib with manageable toxicity and an emerging overall survival signal. Overall, these findings support combination strategies while emphasizing the need for longer follow-up and better patient selection.
ZUSDURI (Mitomycin) Demonstrates Sustained Efficacy Across EORTC Risk Groups in Recurrent NMIBC
ZUSDURI (mitomycin) delivers durable tumor control in recurrent low‑grade, intermediate‑risk NMIBC, with 79.6% complete responses at three months and 72.2% event-free survival at 24 months. Effective across all EORTC risk groups, it offers a promising option for bladder preservation and long-term disease management.
